OBJECTIVE:　To　develop　a　quick,　sensitive　and　accurate　high　performance　liquid　chromatography　tandem　mass　spectrometric(HPLC-MS/MS)　method　for　quantification　of　VND3207　and　its　metabolites　in　rat　plasma　and　to　investigate　pharmacokinetics　of　VND3207　in　SD　rats.　METHODS:　Rats　were　ig　given　VND3207　70　mg·kg-1.　Blood　samples　were　collected　and　separated　by　liquid　chromatography　on　a　C18　reversion　phase　chromatographic　column　with　gradient　elution.　Concentration　of　VND3207　and　its　metabolites　syringic　acid　and　syringic　alcohol　were　detected　by　HPLC-MS/MS　in　positive　multiple　reaction　monitoring　mode.　Pharmacokinetic　parameters　of　VND3207　and　its　metabolites　were　calculated.　RESULTS:　Calibration　curves　of　VND3207　and　its　metabolites　syringic　acid　and　syringic　alcohol　were　linear　within　the　range　of　2-2000　μg·L　-1,　ranged　from　quantification　limit　2　μg·L-1.　Intra-　and　inter-day　precision　was　both　less　than　15%,　and　accuracy　with　91.2%-110.7%.　The　concentrations　of　VND3207　and　its　metabolites　were　detected　in　plasma　of　rats　up　to　12　h　after　VND3207　was　ig　given　to　rats.　AUC　0-∞　of　VND3207,　syringic　acid　and　syringic　alcohol　were　19.37　±　10.56,　1825.32　±　719.97　and　(9.89　±　1.75)　mg·L-1·min,　and　T1/2　was　78.0　±　44.6,　114.4　±　17.9　and　(66.0　±　23.8)　min,　respectively.　CONCLUSION:　A　quick,　sensitive　and　accurate　HPLC-MS/MS　method　is　developed　for　quantification　of　VND3207　and　its　metabolites　in　rat　plasma.　VND3207　is　absorbed　and　metabolized　rapidly.　A　large　amount　of　VND3207　is　oxidized　to　syringic　acid　while　a　small　amount　is　reduced　to　syringic　alcohol.